PT - JOURNAL ARTICLE AU - Rima Arnaout AU - Lara Curran AU - Yili Zhao AU - Jami C. Levine AU - Erin Chinn AU - Anita J. Moon-Grady TI - Expert-level prenatal detection of complex congenital heart disease from screening ultrasound using deep learning AID - 10.1101/2020.06.22.20137786 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.22.20137786 4099 - http://medrxiv.org/content/early/2020/06/24/2020.06.22.20137786.short 4100 - http://medrxiv.org/content/early/2020/06/24/2020.06.22.20137786.full AB - Congenital heart disease (CHD) is the most common birth defect. Fetal survey ultrasound is recommended worldwide, including five views of the heart that together could detect 90% of complex CHD. In practice, however, sensitivity is as low as 30%. We hypothesized poor detection results from challenges in acquiring and interpreting diagnostic-quality cardiac views, and that deep learning could improve complex CHD detection. Using 107,823 images from 1,326 retrospective echocardiograms and surveys from 18-24 week fetuses, we trained an ensemble of neural networks to (i) identify recommended cardiac views and (ii) distinguish between normal hearts and complex CHD. Finally, (iii) we used segmentation models to calculate standard fetal cardiothoracic measurements. In a test set of 4,108 fetal surveys (0.9% CHD, >4.4 million images, about 400 times the size of the training dataset) the model achieved an AUC of 0.99, 95% sensitivity (95%CI, 84-99), 96% specificity (95%CI, 95-97), and 100% NPV in distinguishing normal from abnormal hearts. Sensitivity was comparable to clinicians’ task-for-task and remained robust on external and lower-quality images. The model’s decisions were based on clinically relevant features. Cardiac measurements correlated with reported measures for normal and abnormal hearts. Applied to guidelines-recommended imaging, ensemble learning models could significantly improve detection of fetal CHD and expand telehealth options for prenatal care at a time when the COVID-19 pandemic has further limited patient access to trained providers. This is the first use of deep learning to ∼double standard clinical performance on a critical and global diagnostic challenge.Competing Interest StatementSome methods used in this work have been filed in a provisional patent application.Funding StatementNo entity other than the authors listed played any role in the design of the study; the collection, analysis, or interpretation of data; writing of the report; or in the decision to submit the paper for publication. This work was supported by the American Heart Association, the National Institutes of Health, and the Department of Defense.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCSF Boston Children's HospitalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to the sensitive nature of patient data (and especially fetuses as a vulnerable population), we are not able to make these data publicly available at this time.